Early increase in eosinophil count may predict long-term hypereosinophilia during dupilumab treatment: a 2-year observational study

Andrea Rampi; Umberto Tanzini; Alessandro Vinciguerra; Giulia Danè; Luca Moroni; Mona-Rita Yacoub; Matteo Trimarchi

doi:10.1002/alr.23212

Early increase in eosinophil count may predict long-term hypereosinophilia during dupilumab treatment: a 2-year observational study

Int Forum Allergy Rhinol. 2023 Dec;13(12):2244-2247. doi: 10.1002/alr.23212. Epub 2023 Jul 1.

Authors

Andrea Rampi^{1

2}, Umberto Tanzini^{1

2}, Alessandro Vinciguerra³, Giulia Danè¹, Luca Moroni^{2

4}, Mona-Rita Yacoub⁴, Matteo Trimarchi^{1

2

5}

Affiliations

¹ Otorhinolaryngology Unit, Division of Head and Neck department, IRCCS San Raffaele Scientific Institute, Milan, Italy.
² School of Medicine, Vita-Salute San Raffaele University, Milan, Italy.
³ Otorhinolaryngology and Skull Base Center, AP-HP, Hospital Lariboisière, Paris, France.
⁴ Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy.
⁵ Department of Otolaryngology-Head and Neck Surgery, Ente Ospedaliero Cantonale, Ospedale Regionale di Lugano - Università della Svizzera Italiana, Lugano, Switzerland.

PMID: 37316962
DOI: 10.1002/alr.23212

Abstract

In a limited subset of patients, dupilumab-induced hypereosinophilia is persistent. Two-month follow-up eosinophil count may predict long-lasting hypereosinophilia.

Keywords: chronic rhinosinusitis; eosinophilic rhinitis and nasal polyposis; paranasal sinus diseases; therapeutics.

Publication types

Observational Study

MeSH terms

Chronic Disease
Eosinophilia* / chemically induced
Eosinophils
Humans
Nasal Polyps*
Rhinitis*
Sinusitis*

Substances

dupilumab